Fibrinogen receptor antagonist

- Merck & Co., Inc.
Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

3. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

4. A method for inhibiting the aggregation of blood platelets in a mammal, comprising treating the mammal in need thereof with a platelet aggregation inhibting amount of a composition of claim 3.

5. A method for inhibiting the aggregation of blood platelets in a mammal, by blocking fibrinogen from acting at its receptor site, comprising treating the mammal in need thereof with a fibrinogen receptor blocking amount of a composition of claim 3.

Referenced Cited
U.S. Patent Documents
4064255 December 20, 1977 Cahmpseix et al.
4122255 October 24, 1978 Krapcho
4243807 January 6, 1981 Friebe et al.
4622331 November 11, 1986 Jozic
5030654 July 9, 1991 Barnish et al.
5064814 November 12, 1991 Klein et al.
5281585 January 25, 1994 Duggan et al.
5665882 September 9, 1997 Chung
Foreign Patent Documents
0 352 249 January 1990 EPX
0 372 486 June 1990 EPX
0 381 033 August 1990 EPX
0 384 362 August 1990 EPX
0 405 537 January 1991 EPX
0 478 328 April 1992 EPX
0 478 362 April 1992 EPX
97/14417 April 1997 WOX
Patent History
Patent number: 5889023
Type: Grant
Filed: May 5, 1997
Date of Patent: Mar 30, 1999
Assignee: Merck & Co., Inc. (Rahway, NJ)
Inventors: John H. Hutchinson (Philadelphia, PA), George D. Hartman (Lansdale, PA), Wasyl Halczenko (Lansdale, PA)
Primary Examiner: Evelyn Mei Huang
Attorneys: Richard S. Parr, Melvin Winokur
Application Number: 8/841,884